Technical Analysis for BLRX - BioLineRx Ltd.

Grade Last Price % Change Price Change
grade F 2.84 -1.39% -0.04
BLRX closed down 1.39 percent on Thursday, September 19, 2019, on 1.73 times normal volume.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical BLRX trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Outside Day Range Expansion 0.00%
Fell Below 20 DMA Bearish -1.39%
1,2,3 Pullback Bullish Bullish Swing Setup -1.39%
Boomer Buy Setup Bullish Swing Setup -1.39%
Narrow Range Bar Range Contraction -1.39%
Inside Day Range Contraction -1.39%
Crossed Above 20 DMA Bullish -3.07%
1,2,3 Pullback Bullish Bullish Swing Setup -3.07%

Older signals for BLRX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates. The company's development pipeline consists of six clinical-stage therapeutic candidates, including BL-1020, which is in Phase II/III clarity trial to enhance cognitive function in schizophrenia patients; BL-1040, a novel polymer solution that is under pivotal CE-Mark registration trial for use in the prevention of pathological cardiac remodeling following a myocardial infarction; and BL-5010, a medical device, which has completed Phase I/II clinical trials for the non-surgical removal of skin lesions. Its development pipeline also includes BL-1021 that is in Phase Ia clinical trial for the treatment of neuropathic pain, or pain that results from damage to nerve fibers; BL-7040, which is in Phase II clinical trial for the treatment of inflammatory bowel disease; and BL-8040, a peptide that has completed Phase I/II clinical trial for the treatment of acute myeloid leukemia and other hematological cancers. The company also has six products in various pre-clinical development stages for indications, such as central nervous system diseases, infectious diseases, cardiovascular, and autoimmune diseases. In addition, it operates a biotechnology incubator to evaluate therapeutic candidates. BioLineRx Ltd. has license agreements with Genoscience; Compugen Ltd.; RFS Pharma; Yissum and University of Genoa, Italy; Gestion Univalor, Limited Partnership; Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd.; and Ikaria. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
Biotechnology Health Pain Infectious Diseases Drug Discovery Autoimmune Diseases Clinical Trial Pharmacology Schizophrenia Acute Myeloid Leukemia Inflammatory Bowel Disease Design Of Experiments Clinical Research Central Nervous System Diseases Hematological Cancers Treatment Of Acute Myeloid Leukemia Biotechnology Companies Compugen Treatment Of Inflammatory Bowel Disease
Is BLRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 27.6
52 Week Low 2.32
Average Volume 67,569
200-Day Moving Average 5.8073
50-Day Moving Average 3.3738
20-Day Moving Average 2.8903
10-Day Moving Average 2.887
Average True Range 0.2031
ADX 29.69
+DI 20.0547
-DI 19.9549
Chandelier Exit (Long, 3 ATRs ) 3.0327
Chandelier Exit (Short, 3 ATRs ) 2.9293
Upper Bollinger Band 3.1246
Lower Bollinger Band 2.656
Percent B (%b) 0.39
BandWidth 16.21285
MACD Line -0.1434
MACD Signal Line -0.1901
MACD Histogram 0.0467
Fundamentals Value
Market Cap 271.55 Million
Num Shares 95.6 Million
EPS -0.28
Price-to-Earnings (P/E) Ratio -10.14
Price-to-Sales 0.00
Price-to-Book 1.78
PEG Ratio 0.18
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.30
Resistance 3 (R3) 3.30 3.14 3.22
Resistance 2 (R2) 3.14 3.03 3.14 3.20
Resistance 1 (R1) 2.99 2.95 2.91 2.99 3.17
Pivot Point 2.84 2.84 2.80 2.84 2.84
Support 1 (S1) 2.69 2.72 2.61 2.69 2.51
Support 2 (S2) 2.53 2.65 2.53 2.48
Support 3 (S3) 2.38 2.53 2.46
Support 4 (S4) 2.38